



ISSN: 0067-2904

Detection of the Antiseptic Resistance Gene among *Pseudomonas aeruginosa* Isolates

Akhlas Na'ama Khudair*, Suhad Saad Mahmood

Department of Biotechnology, College of Science, University of Baghdad, Baghdad, Iraq

Received: 19/2/2020

Accepted: 30/4/2020

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen that causes a number of infections in immunocompromised patients. This organism appears to improve resistance to many antimicrobial agents and a high percentage of clinical isolates of *P. aeruginosa* exhibit multidrug resistance (MDR) phenotype. The purpose of this study is to screen the antibiotic susceptibility patterns and the prevalence of *qacE delta1* gene among bacterial isolates. Accordingly, 145 samples were collected from different clinical sources from patients who admitted to different hospitals in Baghdad city in a period ranged 23/8/2018-1/1/2019. The isolates were diagnosed as *P. aeruginosa* based on routine bacteriological methods and confirmed by a molecular method using *16SrRNA* gene. The antibiotic susceptibility test was performed to all identified isolates by Kirby-Bauer Disk Diffusion method using ten types of antibiotics. The results of antibiotics susceptibility test revealed high levels of resistance toward Piperacillin (72.22%), Trimethoprim (68%), Cefazidime (68%), Colistin (40.28%), and Levofloxacin (33.33%). And, the minimum inhibitory concentration (MIC) of Ceftrime was tested using different concentrations (2.048 to 0.004 μ g/100 μ l) and the results showed that MIC values ranged between 2.048 and 0.016 μ g/100 μ L, and the concentration of 0.256 μ g/100 μ l was more frequent. Finally, the prevalence of *qacE delta1* gene among bacterial isolates was detected in percentage 63.88% among bacterial isolates.

Keywords: *pseudomonas aeruginosa*, *qacEdelta 1* gene, Antiseptic.

الكشف عن جين مقاومة المطهرات بين عزلات الزائفة الزنجارية

أخلاص نعمة خضير*, سهاد سعد محمود

قسم التقنيات الاحيائية، كلية العلوم، جامعة بغداد، بغداد، العراق

الخلاصة

تعتبر بكتريا *Pseudomonas aeruginosa* من الممرضات الانتهازية التي تسبب عدد من الاصابات للأشخاص ذو المناعة المنخفضة. يبدو أن هذا الكائن الحي يحسن المقاومة للعديد من العوامل المضادة للميكروبات ونسبة عالية من العزلات السريرية لـ *P. aeruginosa* تظهر المقاومة المتعددة للأدوية (MDR). الغرض من هذه الدراسة هو فحص أنماط الحساسية للمضادات الحيوية وانتشار الجين *qacE delta1* بين العزلات البكتيرية. تم في هذه الدراسة جمع 145 عينة من مصادر سريرية مختلفة من مرضى دخلوا مستشفيات مختلفة في مدينة بغداد في الفترة من 23/8/2018 / 1-2019/1. تم تشخيص العزلات

*Email: akhlasnaama1@gmail.com

على أنها *P. aeruginosa* على أساس الطرق البكتريولوجية الروتينية وتم تأكيدها بالطريقة الجزيئية باستخدام جين *16srRNA*. تم إجراء اختبار الحساسية للمضادات الحيوية على جميع العزلات التي تم تحديدها بطريقة Kirby-Bauer Disk Diffusion باستخدام عشرة أنواع من المضادات الحيوية. كشفت نتائج اختبار الحساسية للمضادات الحيوية عن مستوى عالٍ من المقاومة تجاه piperacillin (72.22%) ، trimethoprim (68%) ، Ceftazidime (68%) ، colistin (40.28%) ، levofloxacin (33.33%) . تم اختبار MIC لـ cetrimide باستخدام تراكيز مختلفة (2.048 إلى 0.004 ميكروغرام / 100 ميكرو لتر) وأظهرت النتائج أن قيم MIC تراوحت بين (2.048-0.016) ميكروغرام / 100 ميكرو لتر وكان التخفيف بتركيز 0.256 ميكروغرام / 100 ميكرو لتر أكثر تكرارًا . وأخيرًا ، تم اكتشاف انتشار جين *qacE delta1* بين العزلات البكتيرية بنسبة 63.88%.

Introduction

P. aeruginosa is an ubiquitous non-fermentative bacterium [1]. It is one of the most common causative agents of nosocomial infections, with a high mortality rate that could reach 60% [2,3].

In addition, it is responsible for several inflammations of burns, wounds, urinary tract infections, otitis media, eye infection, endocarditis, brain membrane inflammation (Meningitis), and respiratory infections such as pneumonia, especially in patients with cystic fibrosis [4].

P. aeruginosa infections is a growing global public health concern due to the ability of the bacteria to produce a variety of virulence factors as well as their resistance to the bulk of current antibiotic regimes used in hospitals [5]. In hospitals, biocides (disinfectants and antiseptics like Cetrimide) are used extensively and their effectiveness is very important in controlling microbial populations and preventing the transmission of infections [6,7]. Acquisition of biocide resistant genes can occur through mobile genetic elements (integrons, plasmids, transposons and prophages); bacteria can acquire these genes via horizontal gene transfer from the same or different bacterial species [8].

Biocide resistant genes, which confer resistance to a wide range of antibiotics and antiseptic agents, are located within a gene cassette in the variable region of integron (*intI*) [9].

These genes result in increasing the resistance ability of *P. aeruginosa* strains to antibiotics and biocides. This study aimed to detect the antibiotic susceptibility patterns and determine the prevalence of *qacE delta1* gene among *P. aeruginosa* bacterial isolates.

Sample collection

Totally, 145 samples were obtained from different clinical sources (burns, wounds, respiratory system infections, eye, ear infections, urinary tract infections, cerebral spinal fluid, sputum pus, joints and catheter). The samples were collected from patients who admitted to Baghdad hospitals (The Burn Centre, Baghdad Teaching Hospital, Medical City-Ghazi Hariri for Specialized Surgery, Educational Laboratory, Al-Sadder Hospital, Al-Karamu Hospital, Al-Yarmouk Educational Hospital, and the Burn Centre in Al-Yarmouk Hospital) during the period between 23/8/2018 and 1/1/2019. The clinical samples were identified by routine biochemical tests such as Gram stain, oxidation and fermentation test (O/F), oxidase test, inability to fermentate lactose, and growth on Cetrimide agar medium (Himedia, India).

Antibiotic susceptibility test

All identified isolates (n=72) were subjected to antibiotic susceptibility test that was carried out by Kirby-Bauer diffusion method using different types of antibiotics, including Imipenem (10 µg), Meropenem (10 µg), Trimethoprim (5µg), Aztreonam (30 µg), Tobramycin (10 µg), Gentamycin (10 µg), Levofloxacin (5µg), Ceftazidime (30 µg), Piperacillin (100 µg) and Colistin (10 µg) (Himedia, India). The results of susceptibility were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute [10].

Minimum inhibitory concentration of cetrimide

The MIC test was performed according to a previously published method [10,11].

Cetrimide was dissolved in sterile distilled water to prepare a stock solution of 8,192 µg/ mL, and then it was filtered via filter paper (size 0.22 µm). Later, it was diluted in Mueller Hinton Broth (MHB) medium (Himedia, India) to obtain two fold serial dilutions that ranged from 2.048 to 0.004µg/100µl. Bacterial inoculum was prepared according to the colony suspension method using MHB, and any resulting turbid solutions were visually compared with the McFarland standard for turbidity vs. cell concentration. The result was verified by measuring the absorbance of the suspension

spectrophotometrically on 600 nm. The reading between 0.08 and 0.10 was accepted as equal as the turbidity adjusted to 1×10^8 cfu/ml and equal to 0.5 McFarland.

Then, 100 μ l was taken from stock (bacterial growth) and added into 9.900 μ l normal saline to obtain an inoculum with a concentration of 1.5×10^6 cfu/ml. A 96 well microtiter plate was filled with 100 μ l of MHB, then serial concentrations of Cetrimide (100 μ L) were added to each column, with the corresponding concentration of the target disinfectant. For each test plate, two biocide-free controls were used, the first one was sterility control (200 μ l medium only) and the second was growth control (100 μ l of medium- inoculum suspension). After overnight incubation, resazurin sodium stain was added to each well in plates and incubated for 2-4 hours. The reduction of resazurin stain (purple-blue) to resorufin (pink-colorless) was observed in each well containing the active living cells, while the stain remained as purple-blue in wells that contained dead cells.

Molecular study

DNA extraction

Chromosomal DNA was extracted according to the manufacturer's procedure of Reagent Genomic DNA Kit, Geneaid (Taiwan).

Amplification of *P. aeruginosa* 16s rRNA and qacE delta1 genes

PCR method was performed to amplify 16srRNA and qacE delta1 genes, and specific primers were used (Table-1). These primers were utilized in a 25 μ l reaction solution containing 12.5 μ l of Go Taq®Green Master Mix (Promega, USA), 1 μ l of each primer (10 pmol), 7.5 μ l of DNase RNase free water, and 3 μ l of the purified DNA template. The PCR cycle conditions were: Initial denaturation at 95°C for 5 min, thirty cycles of denaturation at 94°C for 30 sec, annealing at 58°C for 1min, extension at 72°C for 30 sec, and final extension at 72°C for 5 min. The PCR products were separated by gel electrophoresis using 1.5% agarose gel (Thermo Fisher Scientific, USA) and visualized by gel documentation system using ethidium bromide. A 1500 bp DNA Ladder (Bioland -USA) was used to detect the correct amplicon size.

Table 1- Primers sequences of 16srRNA and qacE delta1 genes

Name	Sequence	Product size
16SrRNA	F5' CGGACCTCACGCTATCAGAT3'	249 bp
	R5' CTGCCCTTCCCTCCCAACTTA3'	
qacE delta1	F-5' TAGCGAGGGCTTTACTAA GC3'	207bp
	R5' CCCATACCTACAAAGCCCCA3'	

Result and discussion

72 clinical isolates, out of 145 clinical samples, were identified as *P. aeruginosa* by routine bacteriological methods. In addition, the isolates were subjected to molecular detection by 16srRNA gene to confirm bacterial genus and species as shown in (Figure-3).

P. aeruginosa can cause various clinical infections and it is considered one of the most important problems confronting the world, especially the developing countries. In addition, it is considered as an important cause of nosocomial infections due to its ability to persist in unfavourable environmental conditions by developing biofilms and tolerating the antibiotics, antiseptics, and disinfectants [12].

Susceptibility of *P. aeruginosa* for different antibiotics

Figure-1 demonstrates an obvious resistance among *P. aeruginosa* isolates to Piperacillin (72.22%), Trimethoprim (68%), and Ceftazidime (68%). Moreover, all the isolates showed resistance to Aztronem in a percentage of 47.22%. Also, the resistance percentages to Tobramycin and Gentamycin were 45.83% and 51.39%, respectively. On the other hand, the isolates showed a moderate-high resistance to Meropenem and Imipenem (44.44% and 40.28%, respectively). For the remaining antibiotics (Colistin and Levofloxacin), the resistance values were 40.28% and 33.33%, respectively.

Our study is consistent with a previous report [13] which demonstrated that *P. aeruginosa* isolates were highly resistant to Aztreonam (86.7%), but inconsistent with the same study in relation to Piperacillin resistance rate (93.3%). Another study [14] reported that the isolates of *P. aeruginosa* collected from burn patients who referred to Mottahari hospital in Tehran province, Iran, were resistant to the antibiotics of Aztreonam (80.2%) and Ceftazidime (74.8%). Another study recorded a

different rate of Piperacillin resistance (75%) [4]. Also, in agreement with our results, resistance rates to Piperacillin and ceftazidim were recorded to be 69.9% and 68.8%, respectively [15]. According to the present study, resistance to Imipenem was high, in comparison with previous studies which reported values of 20% [16] and 38.6% [17]. In addition, an earlier work [18] recorded a high rate of resistance to Meropenem (30.6%) among *P. aeruginosa* isolates, which is comparable with recent reports that recorded values of 38.3% [17] and 36.4% [19]. The reason for the high resistance to Meropenem may be related to the excessive use of this drug [18].

The isolates showed highest resistance values to aminoglycosides (Gentamycin and Tobramycin), whereas an earlier study showed a significantly lower resistance to Gentamycin [20]. This study showed a high percentage of Colistin resistance among the tested isolates, while many other studies recorded a high sensitivity that ranged 96%-100% [21, 22]; however, increasing the administration of Colistin to treat the infections caused by the MDR organisms may have resulted in the emergence of Colistin-resistant strains [5].




Figure 1-The percentage of antibiotic susceptibility for *P. aeruginosa* isolates. Aztreonam(ATM), Ceftazidime(CAZ), Colistin(CT), Gentamycin(CN), Imipenem(IPM), Levofloxacin(LEV), Meropenem (MEM), Piperacillin(PRL), Tobramycin (TOB), Trimethoprim(TMP).

Minimum inhibitory concentration of Ceftrimide

The results of MIC of Ceftrimide against *P. aeruginosa* isolates showed that the MIC values ranged between 2.048 and 0.016 µg/100 µl, and the concentration of 0.256 µg/100 µl was more frequent (Figure- 2).




Figure 2-Determination of the minimum inhibitory concentration of ceftriaxone among *P. aeruginosa* isolates by using Resazurin sodium stain (60 μ l per well), with incubation for 2-4 h for the observation of colour change. C-: Column 11 refers to the negative control (blue/purple), C+: Column12 refers to the positive control, MBC: minimum bactericidal concentration.

Molecular detection of *16SrRNA* and biocide resistance gene in *P. aeruginosa* isolates

All the 100 DNA samples of *Pseudomonas spp.* were subjected to molecular identification by PCR amplification technique. The results revealed that 72 isolates (100%) gave positive and specific band size of 249bp. To confirm our results, the products were sent for sequencing and the results were aligned with the NCBI blast tool for *P. aeruginosa*, showing similarity and identity of 100%.




Figure 3-PCR product visualised by 1.5% agarose gel electrophoresis (1hr:30mins) showing the amplification of a 249bp fragment of *16S rRNA* gene of *P. aeruginosa* isolates. M: 1500bp represents ladder, lane 1 represents positive control, lanes 2,-13 represent positive isolates, and lane 14 represents negative control using water instead of gDNA.

The results of molecular detection of *qacE delta 1*, which is responsible for biocides resistance, showed that from a total of 72 extracted DNA samples of *P. aeruginosa*, only 46 isolates (63.88%) were provided a specific band with a molecular size of 207bp, following electrophoresis on 2% agarose gel (Figure-4). A proportion of A study on the Egyptian population [23] indicated that 57.8% of *P. aeruginosa* isolates have this gene. In contrast to our findings, another study reported that 30.5% of the isolates possessed this gene [6], while other studies [24, 25] detected *qacE Delta 1* gene in *P. aeruginosa* isolates with a high incidence rate of 100%.




Figure 4-PCR product on 2% agarose gel electrophoresis (1hr:30mins), representing an amplification profile of *qacE delta 1* gene of *P. aeruginosa* isolates with a specific band size of 207 bp. M:1500bp represents ladder; lanes 2-26 represent positive isolates, lane 1 represents positive control, and lane 27 represents negative control which contains water instead of gDNA.

According to our results, 63.88% of the biocides resistance isolates possessed this gene. As mentioned above, this gene confers the ability to resist both disinfection and sterilization compounds, especially quaternary ammonium compounds (QACs). Out of 26 isolates, 8 isolates did not have this gene but showed resistance to Cetrimide. This might be attributed to membrane impermeability that is resulted from the repeated exposure to chemical disinfectants or excessive use of antibiotics. Moreover, it might be resulted from mutations that lead to a change in the cell wall of bacteria, or proteins known as porins which cause the channels on the wall to narrow, reducing the entry of antimicrobial agents, including antiseptics. In addition, the acquisition of resistance genes from plasmid or transposons leads to failure of disinfection in hospitals and health centers, which renders them sites for spreading the infection [26].

Conclusions

In conclusion, our findings indicate that *P. aeruginosa* isolates showed a high resistance to antibiotics and biocides. Hence, the optimization of antimicrobials use and the control of infection are recommended measures to prevent the increase in the population of drug resistant organisms in the hospitals of Baghdad city.

References

1. Keramati, N., Zeighami, H. and Haghi, F. **2014**. Frequency of Class I and II Integrons in Metallobetalactamase Producing Clinical Isolates of *Pseudomonas Aeruginosa*. *Journal of Zanjan University of Medical Sciences & Health Services.*, **22**(94).
2. Druge, S., Ruiz, S., Vardon-Bouines, F., Grare, M., Labaste, F., Seguin, T., Fourcade, O., Minville, V., Conil, J.M. and Georges, B. **2019**. Risk factors and the resistance mechanisms involved in *Pseudomonas aeruginosa* mutation in critically ill patients. *Journal of intensive care.*, **7**(1): 36.
3. Mehri I., Yousra T., Imen D., Asma B. R., Abdennaceur H. and Maher G. **2013**. Molecular identification and assessment of genetic diversity of fluorescent pseudomonades based on different polymerase chain reaction (PCR) methods. *Journal of Microbial & Biochemical Technology.*, **7**(19): 2103-2113.

4. Al-Azzawi, S.N.A. and Abdullah, R.M. **2018**. Study of the resistance of *P. aeruginosa* isolated from wounds and burns for some disinfectants and antiseptics from some Baghdad hospitals. *Journal of Pharmaceutical Sciences and Research.*, **10**(6): 1481-1484.
5. Pachori, P., Goyal, R. and Gandhi, P. **2019**. Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive care unit; a critical review. *Genes and diseases.*, **6**(2): 109.
6. Kadry, A. A., Serry, F. M., El-Ganiny, A. M. and El-Baz, A. M. **2017**. Integron occurrence is linked to reduced biocide susceptibility in multidrug resistant *Pseudomonas aeruginosa*. *British journal of biomedical science.*, **74**(2): 78-84.
7. Ismail, S. J. and Mahmoud, S. S. **2018**. First detection of New Delhi metallo- β -lactamases variants (NDM-1, NDM-2) among *Pseudomonas aeruginosa* isolated from Iraqi hospitals. *Iranian journal of microbiology.*, **10**(2): 98–103.
8. Blair, J., Webber, M., Baylay, A. *et al.* **2015**. Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol*, **13**: 42–51, <https://doi.org/10.1038/nrmicro3380>.
9. Botelho, J., Grosso, F. and Peixe, L. **2019**. Antibiotic resistance in *Pseudomonas aeruginosa*—Mechanisms, epidemiology and evolution. *Drug Resistance Updates*, **44**: 100640.
10. CLSI . **2018**. Performance Standards for Antimicrobial Disk Susceptibility Testing. 28th ed. CLSI standard M100. Clinical and Laboratory Standards Institute; [http:// www.facm.ucl.ac.be /intranet /CLSI/CLSI-2018-M100-S28](http://www.facm.ucl.ac.be/intranet/CLSI/CLSI-2018-M100-S28).
11. Wiegand, I., Hilpert, K. and Hancock, R. **2008**. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nature Protocols*, **3**: 163–175 <https://doi.org/10.1038/nprot.2007>.
12. Kireççi, E. And Kareem, R. D. **2014**. Antibiotic susceptibility patterns of *Pseudomonas aeruginosa* strains isolated from various clinical specimens. *Sky Journal of Microbiology Research*, **2**: 13-17.
13. Vaez, H., Safaei, H. G. and Faghri, J. **2017**. The emergence of multidrug-resistant clone ST664 *Pseudomonas aeruginosa* in a referral burn hospital, Isfahan, Iran. *Burns and trauma*, **5**: 27. <https://doi.org/10.1186/s41038-017-0092-x>.
14. Salimi, H., Yakhchali, B., Owlia, P. and Lari, A. R. **2010**. Molecular epidemiology and drug susceptibility of *Pseudomonas aeruginosa* strains isolated from burn patients. *Laboratory Medicine.*, **41**(9): 540-544.
15. Nikokar, I., Tishayar, A., Flakiyan, Z., Alijani, K., Rehana-Banisaeed, S., Hossinpour, M., Amir-Alvaei, S. and Araghian, A. **2013**. Antibiotic resistance and frequency of class 1 integrons among *Pseudomonas aeruginosa*, isolated from burn patients in Guilan, Iran. *Iranian journal of microbiology*, **5**(1): 36–41.
16. Bukharie, A. H. and Mowafi, H. A. **2010**. Antimicrobial susceptibility pattern of *Pseudomonas aeruginosa* and antibiotic use in King Fahd hospital of the University in Khobar, Saudi Arabia. *Scientific Journal of King Faisal University (Basic and Applied Sciences.)*, **11**(1): 185-191.
17. Al-Agamy MH, Shibl AM, Samar A, Zaki, SA. and Tawfik AF. **2011**. Antimicrobial resistance pattern and prevalence of metallo- β -lactamases in *Pseudomonas aeruginosa* from Saudi Arabia. *African Journal of Microbiology Research* ., **5**: 5528-5533.
18. Khan, M. A. and Faiz, A. **2016**. Antimicrobial resistance patterns of *Pseudomonas aeruginosa* in tertiary care hospitals of Makkah and Jeddah. *Annals of Saudi medicine.*, **36**(1): 23-28.
19. Asghar, A. H. **2012**. Antimicrobial susceptibility and metallo- β -lactamase production among *Pseudomonas aeruginosa* isolated from Makkah Hospitals. *Pakistan Journal of Medical Sciences.*, **28**(5).
20. Liu, H., Kong, W., Yang, W., Chen, G., Liang, H. and Zhang, Y. **2018**. Multilocus sequence typing and variations in the *oprD* gene of *Pseudomonas aeruginosa* isolated from a hospital in China. *Infection and drug resistance.*, **11**: 45.
21. Yayan, J., Ghebremedhin, B. and Rasche, K. **2015**. Antibiotic Resistance of *Pseudomonas aeruginosa* in Pneumonia at a Single University Hospital Center in Germany over a 10 Year Period PLoS ONE, **10**(10): e0139836 DOI: [10.1371/journal.pone.0139836](https://doi.org/10.1371/journal.pone.0139836).
22. Sader, H. S., Flamm, R. K., Carvalhaes, C. G. and Castanheira, M. **2018**. Antimicrobial Susceptibility of *Pseudomonas aeruginosa* to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. *Antimicrobial agents and chemotherapy*, **62**(12): e01587-18. <https://doi.org/10.1128/AAC.01587-18>.

23. Helal, Z. H. and Khan, M. I. **2015**. QacE and QacE Δ 1 Genes and Their Correlation to Antibiotics and Biocides Resistance *Pseudomonas aeruginosa*. *American Journal of Biomedical Sciences.*, **7**(2).
24. Abdel-Tawab A.A., Nasef AS. and Ibrahim AO. **2016**. Bacteriological and Molecular Studies on Bacteria Causing Omphalitis in Chicks with Regard to Disinfectant Resistance. *Global Veterinaria*, **17**(6): 539-545.
25. Bakheet, A. A., Naglaa, M. A., Sayed, A. H. and Soad, A. N. **2017**. Detection of Disinfectant resistant aerobic bacteria in unhatched chicken eggs. *Benha Vet. Med. J.*, **32**(2): 248-259.
26. Kose, H. and Yapar, N. **2017**. The comparison of various disinfectant efficacy on *Staphylococcus aureus* and *Pseudomonas aeruginosa* biofilm layers. *Turkish journal of medical sciences.*, **47**: 1287-1294.